

AQUINOX PHARMACEUTICALS, INC  
Form 8-K  
May 04, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 4, 2015**

**Aquinox Pharmaceuticals, Inc.**

**(Exact name of Registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction of**  
**incorporation)**

**001-36327**  
**(Commission File Number)**

**98-0542593**  
**(IRS Employer**

**Identification No.)**

**450 887 Great Northern Way,**  
**Vancouver, B.C.**

Edgar Filing: AQUINOX PHARMACEUTICALS, INC - Form 8-K

**Canada, V5T 4T5**

**(Address of principal executive offices, including zip code)**

**Registrant's telephone number, including area code: (604) 629-9223**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events**

On May 4, 2015, Aquinox Pharmaceuticals, Inc. issued a press release announcing that it has reached its target enrollment in the Phase 2 Kinship clinical trial of AQX-1125 for the treatment of atopic dermatitis. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<b>Number</b>	<b>Description</b>
99.1	Press Release of Aquinox Pharmaceuticals, Inc. dated May 4, 2015

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Aquinox Pharmaceuticals, Inc.

By: /s/ Kamran Alam

Name: Kamran Alam

Title: Chief Financial Officer

Date: May 4, 2015

**INDEX TO EXHIBITS**

<b>Number</b>	<b>Description</b>
99.1	Press Release of Aquinox Pharmaceuticals, Inc. dated May 4, 2015